|Articles|October 18, 2012
Low-dose SSRI formulation shows promise for vasomotor symptoms
A new formulation of a selective serotonin receptor inhibitor (SSRI)-low-dose mesylate of paroxetine (LDMP)-shows promise for reducing vasomotor symptoms of menopause, according to results of two studies presented at the North American Menopause Society (NAMS) conference.
Advertisement
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Contemporary OB/GYN
1
NIRVANA: Elinzanetant cuts objective wakefulness in menopausal women
2
Multi-modality impact of elinzanetant's effect on postmenopausal sleep disturbance
3
FDA approves tebipenem pivoxil as first oral carbapenem antibiotic for complicated urinary tract infections
4
Spotlighting menopause and mental health with Jessica Gaulton, MD, MPH
5